GenomeScan is a young enterprise that originated from the long and intensive collaboration between the Leiden University Medical Center (LUMC) and ServiceXS B.V. The company started in 2002 under the name of “ServiceXS”, founded by five young pioneers in Genetics, and changed its name to GenomeScan in 2014.

GenomeScan has extensive technical expertise and access to the latest technologies available for Next Generation Sequencing analysis. Our in-house sequencing technologies include multiple Illumina platforms (NovaSeq6000, HiSeq4000, NextSeq500) and Droplet Digital PCR from Bio-Rad, and access to the sequencing platforms from PacBio (RSII and Sequel) and the newest technologies from 10XGenomics (Chromium). This infrastructure is coupled with established protocols for DNA sequencing (SNP/variants calling, haplotyping, methylation and hydroxy-methylation, WES, WGS) and RNA sequencing (mRNA, smallRNA, long non-coding RNA, miRNA discovery).

GenomeScan has an extensive track-record in participation in FP7 and Horizon 2020 projects. These include:

  • TransPot – Translational Research Network in Prostate Cancer, 2017-2021, H2020-MSCAITN-ETN-2016 – 721746;
  • RETHRIM – Restoring tissue regeneration in patients with visceral Graft versus Host Disease, 2015-2020, H2020-PHC-2014 – 643580;
  • ELBA – European Liquid Biopsy Academy, H2020-MSCA-ITN-2017.
  • MELGEN – MELanomaGenetics, 2015-2019, H2020-MSCA-ITN-2014.